US 3D Bioprinting Market

The American market can be broadly divided into two significant regions: North America and South America. North America, in turn, is further segmented into the United States and Canada. The factors that delineate the market growth dynamics of North America are rooted in robust economic conditions, continual technological advancements, escalating healthcare expenditures, and a surge in investments and funding dedicated to research endeavors.

As indicated by the National Health Expenditure Accounts (NHEA), healthcare spending in the United States exhibited a substantial increase, reaching USD 3.5 trillion or USD 10,739 per person in 2017, compared to USD 3.2 trillion in 2015. This upward trajectory in healthcare spending underscores the significant financial commitment to advancing healthcare infrastructure. Furthermore, the US Department of Health and Human Services (HHS) reported that, in 2015, nearly 123,304 individuals in the US were on waiting lists for organ transplants. The stark reality is that around 30 people succumb each day due to the scarcity of organs available for transplantation. In response to this critical challenge, researchers are pioneering the development of 3D-printed tissues with the goal of fabricating organs, including kidneys, ears, liver, and noses, utilizing bioprinting techniques. This innovation addresses the pressing issue of organ shortages and fosters a growing demand for 3D-bioprinted organs, thereby propelling the regional market growth.

The North American market also benefits from the proliferation of partnerships among companies engaged in cutting-edge research activities. Such collaborations significantly contribute to the burgeoning market landscape. A notable instance is the strategic alliance formed in April 2015 between Organovo Holdings, Inc. and Merck Sharp & Dohme Corp. This multi-year research collaboration agreement granted Merck access to Organovo’s commercial exVive3D TM Human Liver Tissue service. The collaboration aimed not only to facilitate Merck's research initiatives but also to develop diverse custom tissue models using Organovo’s NovoGen Bioprinter Platform, specifically for drug development purposes. These strategic partnerships bolster research activities, providing a significant impetus to market growth.

Moreover, the region's dominance is further underscored by the presence of key market value contributors, including Organovo Holdings, Inc., Nano 3D Biosciences, Inc., Allevi, Aspect Biosystems Ltd., and Dynamic Systems, Inc. These industry leaders play a pivotal role in initiating the market and ensuring the ample availability of cutting-edge products. Their presence not only signifies the early adoption of advanced technologies but also supports the region's ascendancy in the forefront of the market.

In essence, North America stands as a dynamic force in the American market, driven by a confluence of factors such as robust economic conditions, substantial healthcare investments, and innovative research collaborations. The region's commitment to addressing critical healthcare challenges, such as organ shortages, through pioneering technologies like 3D bioprinting, positions it at the forefront of advancements in the field. The collaborative efforts among key industry players further fortify North America's preeminence in the rapidly evolving landscape of innovative medical solutions and bioprinting technologies.